

## 0009 The Impact of Axial Spondyloarthritis on Quality of Life: A Comparison With Patients With Chronic Kidney Disease

Yu Heng Kwan<sup>1</sup>, Warren Fong<sup>2</sup>, Priscilla How<sup>3</sup>, Wee Hwee Lin<sup>3</sup>, Katy Leung<sup>2</sup>, Phang Jie Kie<sup>2</sup>, Lui Nai Lee<sup>2</sup>, Tan Chuen Seng<sup>3</sup>, Rahul Malhotra<sup>1</sup>, Truls Østbye<sup>1</sup>, Julian Thumboo<sup>2</sup>

<sup>1</sup>Duke-NUS Medical School, <sup>2</sup>Singapore General Hospital, <sup>3</sup>National University of Singapore

**Aims:** To assess the impact of axial spondyloarthritis (axSpA) on patients' quality of life (QoL) compared to patients with chronic kidney disease (CKD).

**Methodology:** We conducted secondary analysis of QoL data obtained from patients with axSpA and CKD from 2011 to 2014. Patients with axSpA fulfilled the 2009 ASAS criteria for axSpA while patients with CKD fulfilled the KDOQI guidelines for CKD. QoL was assessed using the SF-36 version 2 and KDQoL-SF for patients with axSpA and CKD respectively. Patients with CKD were sub-categorized to CKD-pre-dialysis, hemodialysis (CKD-HD) and peritoneal dialysis (CKD-PD). Linear regression was used to compare QoL between patients with axSpA and CKD after adjusting for age, gender, ethnicity, education level, and marital status.

**Result:** A total of 765 patients (Mean age: 54.6, 63.0% males, 69.0% Chinese) were analyzed, of which 188 (24.5%) had axSpA. Patients with axSpA had poorer SF-36 bodily pain (BP) scores [axSpA: reference; CKD-pre-dialysis  $\beta$ :11.04,  $p < 0.001$ ; CKD-HD  $\beta$ :9.52,  $p < 0.001$ , CKD-PD  $\beta$ :10.35,  $p < 0.001$ ] and higher general health (GH) scores [axSpA: reference; CKD-pre-dialysis  $\beta$ :-7.87,  $p < 0.001$ ; CKD-HD  $\beta$ :-7.14,  $p < 0.001$ , CKD-PD  $\beta$ :-7.25,  $p < 0.001$ ] as compared to patients with CKD. Generally, patients with axSpA had poorer SF-36 scores than patients with CKD-pre-dialysis and similar SF-36 scores compared to patients with CKD-HD or CKD-PD.

**Conclusion:** The burden of axSpA on QoL is not trivial and is comparable to patients with CKD-HD or CKD-PD. Clinicians should seek to monitor the impact of axSpA on QoL and develop interventions to improve the QoL of patients with axSpA.